MarketResearchReportStore adds "CSL Ltd - Product Pipeline Review - 2016" latest studies, published in March 2017. It is a professional and in-depth study on the current state.

For a sample of this report, please email at: [email protected]

Description
Summary
‘CSL Ltd - Product Pipeline Review - 2016’, provides an overview of the CSL Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by CSL Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of CSL Ltd
- The report provides overview of CSL Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses CSL Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features CSL Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Request Sample Copy, please email at: [email protected]

Table Of Contents
CSL Ltd Snapshot 6
CSL Ltd Overview 6
Key Facts 6
CSL Ltd - Research and Development Overview 7
Key Therapeutic Areas 7
CSL Ltd - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
CSL Ltd - Pipeline Products Glance 17
CSL Ltd - Late Stage Pipeline Products 17
Pre-Registration Products/Combination Treatment Modalities 17
Phase III Products/Combination Treatment Modalities 18
CSL Ltd - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
CSL Ltd - Early Stage Pipeline Products 21
Preclinical Products/Combination Treatment Modalities 21
Discovery Products/Combination Treatment Modalities 22
CSL Ltd - Drug Profiles 23
(coagulation factor II (human) + coagulation factor VII (human) + coagulation factor IX (human) + coagulation factor X (human) + protein C (human) + protein S (human)) - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Antibodies for Undisclosed Indication - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
antihemophilic factor (recombinant), single chain - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
C1 esterase inhibitor (human) - Drug Profile 28
Product Description 28
Mechanism Of Action 28

Browse Complete Report with TOC @
https://www.marketresearchreportstore.com/shop/csl-ltd-product-pipeline-review-2016

For report sample or more information, please feel free to contact us:
Shirley | Sales Director
Call: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/

About Us
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best.